Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 23, 2026 Filed Mar 24, 2026 20:02 UTC |
Lazar David E.Director
|
SaleSeries AAA Convertible Non-Redeemable Preferred Stock · Derivative | 700,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000921895-26-000788 · form412227indp_03232026.xml · derivative · entry 2 Lazar David E. · CIK 0001932843 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 105,000,000 shares Expires not disclosed F1 · security: On March 19, 2026, David E. Lazar (the "Reporting Person") entered into a Securities Purchase Agreement pursuant to which the Reporting Person sold all of his title and interest in (i) all 700,000 shares of Series AAA Preferred Stock (convertible into an aggregate of 105,000,000 shares of the Issuer's common stock) held by the Reporting Person and (ii) 196,800 shares of the Reporting Person's Series AA Preferred Stock (convertible into an aggregate of 3,936,000 shares of the Issuer's common stock), as well as all of the Reporting Person's rights, title and interest in the Series AA Preferred Stock and Series AAA Preferred Stock under a securities purchase agreement dated December 22, 2025 (the "March 2026 Transaction"). The closing of the March 2026 Transaction occurred on March 23, 2026. Following the March 2026 Transaction, the Reporting Person retained 103,200 shares of Series AA Preferred Stock, convertible into an aggregate of 2,064,000 shares of the Issuer's common stock. F4 · derivative.exercise_price: The Series AAA Preferred Stock is convertible at the option of the holder for no additional consideration. F1 · price: On March 19, 2026, David E. Lazar (the "Reporting Person") entered into a Securities Purchase Agreement pursuant to which the Reporting Person sold all of his title and interest in (i) all 700,000 shares of Series AAA Preferred Stock (convertible into an aggregate of 105,000,000 shares of the Issuer's common stock) held by the Reporting Person and (ii) 196,800 shares of the Reporting Person's Series AA Preferred Stock (convertible into an aggregate of 3,936,000 shares of the Issuer's common stock), as well as all of the Reporting Person's rights, title and interest in the Series AA Preferred Stock and Series AAA Preferred Stock under a securities purchase agreement dated December 22, 2025 (the "March 2026 Transaction"). The closing of the March 2026 Transaction occurred on March 23, 2026. Following the March 2026 Transaction, the Reporting Person retained 103,200 shares of Series AA Preferred Stock, convertible into an aggregate of 2,064,000 shares of the Issuer's common stock. F5 · derivative.expiration_date: The Series AAA Preferred Stock is perpetual and therefore has no expiration date. Read SEC document |
| March 23, 2026 Filed Mar 24, 2026 20:02 UTC |
Lazar David E.Director
|
SaleSeries AA Convertible Non-Redeemable Preferred Stock · Derivative | 196,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000921895-26-000788 · form412227indp_03232026.xml · derivative · entry 1 Lazar David E. · CIK 0001932843 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,200 Underlying: Common Stock · 3,936,000 shares Expires not disclosed F1 · security: On March 19, 2026, David E. Lazar (the "Reporting Person") entered into a Securities Purchase Agreement pursuant to which the Reporting Person sold all of his title and interest in (i) all 700,000 shares of Series AAA Preferred Stock (convertible into an aggregate of 105,000,000 shares of the Issuer's common stock) held by the Reporting Person and (ii) 196,800 shares of the Reporting Person's Series AA Preferred Stock (convertible into an aggregate of 3,936,000 shares of the Issuer's common stock), as well as all of the Reporting Person's rights, title and interest in the Series AA Preferred Stock and Series AAA Preferred Stock under a securities purchase agreement dated December 22, 2025 (the "March 2026 Transaction"). The closing of the March 2026 Transaction occurred on March 23, 2026. Following the March 2026 Transaction, the Reporting Person retained 103,200 shares of Series AA Preferred Stock, convertible into an aggregate of 2,064,000 shares of the Issuer's common stock. F2 · derivative.exercise_price: The Series AA Preferred Stock is convertible at the option of the holder for no additional consideration. F1 · price: On March 19, 2026, David E. Lazar (the "Reporting Person") entered into a Securities Purchase Agreement pursuant to which the Reporting Person sold all of his title and interest in (i) all 700,000 shares of Series AAA Preferred Stock (convertible into an aggregate of 105,000,000 shares of the Issuer's common stock) held by the Reporting Person and (ii) 196,800 shares of the Reporting Person's Series AA Preferred Stock (convertible into an aggregate of 3,936,000 shares of the Issuer's common stock), as well as all of the Reporting Person's rights, title and interest in the Series AA Preferred Stock and Series AAA Preferred Stock under a securities purchase agreement dated December 22, 2025 (the "March 2026 Transaction"). The closing of the March 2026 Transaction occurred on March 23, 2026. Following the March 2026 Transaction, the Reporting Person retained 103,200 shares of Series AA Preferred Stock, convertible into an aggregate of 2,064,000 shares of the Issuer's common stock. F3 · derivative.expiration_date: The Series AA Preferred Stock is perpetual and therefore has no expiration date. Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 16:06 UTC |
Jabbour Jerome DDirector
|
GrantOption to Buy Common Stock · Derivative | 25,000 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001493152-26-008330 · ownership.xml · derivative · entry 1 Jabbour Jerome D · CIK 0001698838 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2036-02-26 F1 · derivative.exercise_date: The Reporting Person acquired options to purchase 25,000 shares of common stock pursuant to the Issuer's non-employee director compensation program. The stock options vest over three years commencing from the date of grant in equal quarterly installments subject to continued service on the Issuer's board of directors through each vesting date. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 21:15 UTC |
Meckler Jeffrey ADirector · Co-Chief Executive Officer
|
GrantWarrants (right to buy) · Derivative | 12,136 | Not disclosed Strike: $1.75 | Not disclosed |
DisclosureSEC source: 0001493152-26-006707 · ownership.xml · derivative · entry 6 Meckler Jeffrey A · CIK 0001506916 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,136 Underlying: Common Stock · 12,136 shares Expires 2030-07-27 F1 · price: Effective February 11, 2026, the Board of Directors of the Company approved a unilateral reduction in the per share exercise price of the warrants to $1.75. All of the other terms of the warrants remained unchanged. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 21:15 UTC |
Meckler Jeffrey ADirector · Co-Chief Executive Officer
|
Disposition to issuerWarrants (right to buy) · Derivative | 12,136 | Not disclosed Strike: $8.30 | Not disclosed |
DisclosureSEC source: 0001493152-26-006707 · ownership.xml · derivative · entry 5 Meckler Jeffrey A · CIK 0001506916 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,136 shares Expires 2030-07-27 F1 · price: Effective February 11, 2026, the Board of Directors of the Company approved a unilateral reduction in the per share exercise price of the warrants to $1.75. All of the other terms of the warrants remained unchanged. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 21:15 UTC |
Meckler Jeffrey ADirector · Co-Chief Executive Officer
|
GrantWarrants (right to buy) · Derivative | 1,519 | Not disclosed Strike: $1.75 | Not disclosed |
DisclosureSEC source: 0001493152-26-006707 · ownership.xml · derivative · entry 4 Meckler Jeffrey A · CIK 0001506916 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,519 Underlying: Common Stock · 1,519 shares Expires 2029-11-25 F1 · price: Effective February 11, 2026, the Board of Directors of the Company approved a unilateral reduction in the per share exercise price of the warrants to $1.75. All of the other terms of the warrants remained unchanged. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 21:15 UTC |
Meckler Jeffrey ADirector · Co-Chief Executive Officer
|
Disposition to issuerWarrants (right to buy) · Derivative | 1,519 | Not disclosed Strike: $29.40 | Not disclosed |
DisclosureSEC source: 0001493152-26-006707 · ownership.xml · derivative · entry 3 Meckler Jeffrey A · CIK 0001506916 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,519 shares Expires 2029-11-25 F1 · price: Effective February 11, 2026, the Board of Directors of the Company approved a unilateral reduction in the per share exercise price of the warrants to $1.75. All of the other terms of the warrants remained unchanged. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 21:15 UTC |
Meckler Jeffrey ADirector · Co-Chief Executive Officer
|
GrantWarrants (right to buy) · Derivative | 3,033 | Not disclosed Strike: $1.75 | Not disclosed |
DisclosureSEC source: 0001493152-26-006707 · ownership.xml · derivative · entry 2 Meckler Jeffrey A · CIK 0001506916 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,033 Underlying: Common Stock · 3,033 shares Expires 2029-08-08 F1 · price: Effective February 11, 2026, the Board of Directors of the Company approved a unilateral reduction in the per share exercise price of the warrants to $1.75. All of the other terms of the warrants remained unchanged. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 21:15 UTC |
Meckler Jeffrey ADirector · Co-Chief Executive Officer
|
Disposition to issuerWarrants (right to buy) · Derivative | 3,033 | Not disclosed Strike: $47.60 | Not disclosed |
DisclosureSEC source: 0001493152-26-006707 · ownership.xml · derivative · entry 1 Meckler Jeffrey A · CIK 0001506916 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,033 shares Expires 2029-08-08 F1 · price: Effective February 11, 2026, the Board of Directors of the Company approved a unilateral reduction in the per share exercise price of the warrants to $1.75. All of the other terms of the warrants remained unchanged. Read SEC document |
| January 20, 2026 Filed Jan 23, 2026 02:57 UTC |
Ben-Tzvi AvrahamDirector
|
GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-003293 · ownership.xml · nonDerivative · entry 1 Ben-Tzvi Avraham · CIK 0001944721 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,100 F1 · price: The Reporting Person acquired 25,000 shares of restricted common stock of the Issuer pursuant to a consulting agreement dated January 20, 2026, which shares vested 100% upon grant. F2 · balance_after: Includes 100 shares of common stock of the Issuer held in a Roth IRA. Read SEC document |
| January 07, 2026 Filed Jan 23, 2026 02:56 UTC |
NATAN DAVIDDirector
|
GrantOption to Buy Common Stock · Derivative | 25,000 | $0.00 Strike: $2.69 | $0.00 |
DisclosureSEC source: 0001493152-26-003292 · ownership.xml · derivative · entry 1 NATAN DAVID · CIK 0001253108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2036-01-07 F1 · derivative.exercise_date: The Reporting Person acquired options to purchase 25,000 shares of common stock pursuant to the Issuer's non-employee director compensation program. The stock options vest over three years commencing from the date of grant in equal quarterly installments subject to continued service on the Issuer's board of directors through each vesting date. Read SEC document |
| December 23, 2025 Filed Jan 23, 2026 02:57 UTC |
Ben-Tzvi AvrahamDirector
|
GrantOption to Buy Common Stock · Derivative | 25,000 | $0.00 Strike: $1.95 | $0.00 |
DisclosureSEC source: 0001493152-26-003293 · ownership.xml · derivative · entry 2 Ben-Tzvi Avraham · CIK 0001944721 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2035-12-23 F3 · price: The Reporting Person acquired options to purchase 25,000 shares of common stock pursuant to the Issuer's non-employee director compensation program. The stock options vest over three years commencing from the date of grant in equal quarterly installments subject to continued service on the Board through each vesting date. F3 · derivative.exercise_date: The Reporting Person acquired options to purchase 25,000 shares of common stock pursuant to the Issuer's non-employee director compensation program. The stock options vest over three years commencing from the date of grant in equal quarterly installments subject to continued service on the Board through each vesting date. Read SEC document |
| December 22, 2025 Filed Dec 29, 2025 16:01 UTC |
Newman Michael JamesDirector · CSO and Director
|
GrantCommon Stock | 52,204 | $2.03 | $105,974.12 |
DisclosureSEC source: 0001493152-25-029354 · ownership.xml · nonDerivative · entry 1 Newman Michael James · CIK 0001876315 · Director · CSO and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,074 F1 · shares: The Reporting Person acquired 52,204 shares of common stock pursuant to an amendment to his employment agreement, in connection with the signing of a securities purchase agreement, dated December 22, 2025. Read SEC document |
| December 22, 2025 Filed Dec 29, 2025 21:01 UTC |
Meckler Jeffrey ADirector · Co-Chief Executive Officer · 10% owner
|
GrantCommon Stock | 216,617 | $2.03 | $439,732.51 |
DisclosureSEC source: 0001493152-25-029355 · ownership.xml · nonDerivative · entry 1 Meckler Jeffrey A · CIK 0001506916 · Director · Co-Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 229,929 F1 · shares: The Reporting Person acquired 216,617 shares of common stock pursuant to an amendment to his employment agreement, in connection with the signing of a securities purchase agreement, dated December 22, 2025. Read SEC document |
| December 22, 2025 Filed Dec 29, 2025 16:01 UTC |
Linscott Walt AddisonChief Operating Officer
|
GrantCommon Stock | 54,421 | $2.03 | $110,474.63 |
DisclosureSEC source: 0001493152-25-029353 · ownership.xml · nonDerivative · entry 1 Linscott Walt Addison · CIK 0001648585 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,426 F1 · shares: The Reporting Person acquired 54,421 shares of common stock pursuant to an amendment to his employment agreement, in connection with the signing of a securities purchase agreement, dated December 22, 2025. Read SEC document |
| December 22, 2025 Filed Dec 29, 2025 16:01 UTC |
Sassi NirChief Financial Officer
|
GrantCommon Stock | 26,758 | $2.03 | $54,318.74 |
DisclosureSEC source: 0001493152-25-029356 · ownership.xml · nonDerivative · entry 1 Sassi Nir · CIK 0001760673 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,758 F1 · shares: The Reporting Person acquired 26,758 shares of common stock pursuant to an amendment to his employment agreement, in connection with the signing of a securities purchase agreement, dated December 22, 2025. Read SEC document |
| July 27, 2025 Filed Jul 29, 2025 20:15 UTC |
Meckler Jeffrey ADirector · Chief Executive Officer
|
GrantCommon Stock Warrants · Derivative | 12,136 | $8.30 Strike: $8.30 | $100,757.93 |
DisclosureSEC source: 0001641172-25-021376 · ownership.xml · derivative · entry 2 Meckler Jeffrey A · CIK 0001506916 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,688 Underlying: Common Stock · 12,136 shares Expires 2030-07-27 F1 · shares: The Reporting Person acquired 6,068 shares of common stock and 12,136 warrants to purchase common stock from the Issuer following the mandatory conversion of a convertible note that the Reporting Person acquired from the Issuer in a private placement in June 2025 at a conversion price of $8.3024, which is equal to 80% of the average closing price of the Issuer's shares of common stock on the Nasdaq Capital Market for the five trading days immediately preceding and including the conversion date of July 27, 2025. F1 · price: The Reporting Person acquired 6,068 shares of common stock and 12,136 warrants to purchase common stock from the Issuer following the mandatory conversion of a convertible note that the Reporting Person acquired from the Issuer in a private placement in June 2025 at a conversion price of $8.3024, which is equal to 80% of the average closing price of the Issuer's shares of common stock on the Nasdaq Capital Market for the five trading days immediately preceding and including the conversion date of July 27, 2025. Read SEC document |
| July 27, 2025 Filed Jul 29, 2025 20:15 UTC |
Meckler Jeffrey ADirector · Chief Executive Officer
|
GrantCommon Stock | 6,068 | $8.30 | $50,378.96 |
DisclosureSEC source: 0001641172-25-021376 · ownership.xml · nonDerivative · entry 1 Meckler Jeffrey A · CIK 0001506916 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,312 F1 · shares: The Reporting Person acquired 6,068 shares of common stock and 12,136 warrants to purchase common stock from the Issuer following the mandatory conversion of a convertible note that the Reporting Person acquired from the Issuer in a private placement in June 2025 at a conversion price of $8.3024, which is equal to 80% of the average closing price of the Issuer's shares of common stock on the Nasdaq Capital Market for the five trading days immediately preceding and including the conversion date of July 27, 2025. F1 · price: The Reporting Person acquired 6,068 shares of common stock and 12,136 warrants to purchase common stock from the Issuer following the mandatory conversion of a convertible note that the Reporting Person acquired from the Issuer in a private placement in June 2025 at a conversion price of $8.3024, which is equal to 80% of the average closing price of the Issuer's shares of common stock on the Nasdaq Capital Market for the five trading days immediately preceding and including the conversion date of July 27, 2025. Read SEC document |
| June 10, 2025 Filed Jun 11, 2025 16:05 UTC |
Karah HilaDirector
|
GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0001641172-25-014692 · ownership.xml · derivative · entry 1 Karah Hila · CIK 0001668116 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2035-06-10 F1 · derivative.exercise_date: The stock option vests and becomes exercisable on June 10, 2026. Read SEC document |
| June 10, 2025 Filed Jun 11, 2025 20:05 UTC |
Hayes William BDirector
|
GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0001641172-25-014691 · ownership.xml · derivative · entry 1 Hayes William B · CIK 0001320940 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2035-06-10 F1 · derivative.exercise_date: The stock option vests and becomes exercisable on June 10, 2026. Read SEC document |
| June 10, 2025 Filed Jun 11, 2025 16:05 UTC |
Martell RobertDirector
|
GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0001641172-25-014694 · ownership.xml · derivative · entry 1 Martell Robert · CIK 0001529922 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2035-06-10 F1 · derivative.exercise_date: The stock option vests and becomes exercisable on June 10, 2026. Read SEC document |
| June 10, 2025 Filed Jun 11, 2025 16:05 UTC |
MADDALUNA ANTHONY JDirector
|
GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0001641172-25-014693 · ownership.xml · derivative · entry 1 MADDALUNA ANTHONY J · CIK 0001566333 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2035-06-10 F1 · derivative.exercise_date: The stock option vests and becomes exercisable on June 10, 2026. Read SEC document |
| June 10, 2025 Filed Jun 11, 2025 20:05 UTC |
Pomerantz RogerDirector
|
GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0001641172-25-014695 · ownership.xml · derivative · entry 1 Pomerantz Roger · CIK 0001614936 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-06-10 F1 · derivative.exercise_date: The stock option vests and becomes exercisable on June 10, 2026. Read SEC document |
| June 10, 2025 Filed Jun 11, 2025 20:05 UTC |
Gilbert Mark JohnDirector
|
GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0001641172-25-014690 · ownership.xml · derivative · entry 1 Gilbert Mark John · CIK 0001897698 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2035-06-10 F1 · derivative.exercise_date: The stock option vests and becomes exercisable on June 10, 2026. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 16:15 UTC |
Karah HilaDirector
|
Disposition to issuerStock Option (right to buy) · Derivative | 250 | $0.39 Strike: $355.20 | $97.50 |
DisclosureSEC source: 0001641172-25-003821 · ownership.xml · derivative · entry 4 Karah Hila · CIK 0001668116 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 250 shares Expires 2025-06-28 F1 · price: The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 16:15 UTC |
Karah HilaDirector
|
Disposition to issuerStock Option (right to buy) · Derivative | 281 | $0.39 Strike: $480.00 | $109.59 |
DisclosureSEC source: 0001641172-25-003821 · ownership.xml · derivative · entry 3 Karah Hila · CIK 0001668116 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 281 shares Expires 2026-05-22 F1 · price: The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 16:15 UTC |
Karah HilaDirector
|
Disposition to issuerStock Option (right to buy) · Derivative | 250 | $0.39 Strike: $388.64 | $97.50 |
DisclosureSEC source: 0001641172-25-003821 · ownership.xml · derivative · entry 2 Karah Hila · CIK 0001668116 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 250 shares Expires 2026-06-28 F1 · price: The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 16:15 UTC |
Karah HilaDirector
|
Disposition to issuerStock Option (right to buy) · Derivative | 500 | $0.39 Strike: $24.60 | $195.00 |
DisclosureSEC source: 0001641172-25-003821 · ownership.xml · derivative · entry 1 Karah Hila · CIK 0001668116 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 500 shares Expires 2027-07-15 F1 · price: The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 20:15 UTC |
Hayes William BDirector
|
Disposition to issuerStock Option (right to buy) · Derivative | 250 | $0.50 Strike: $355.20 | $125.00 |
DisclosureSEC source: 0001641172-25-003820 · ownership.xml · derivative · entry 3 Hayes William B · CIK 0001320940 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 250 shares Expires 2025-06-28 F1 · price: The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 20:15 UTC |
Hayes William BDirector
|
Disposition to issuerStock Option (right to buy) · Derivative | 250 | $0.50 Strike: $388.64 | $125.00 |
DisclosureSEC source: 0001641172-25-003820 · ownership.xml · derivative · entry 2 Hayes William B · CIK 0001320940 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 250 shares Expires 2026-06-28 F1 · price: The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 20:15 UTC |
Hayes William BDirector
|
Disposition to issuerStock Option (right to buy) · Derivative | 500 | $0.50 Strike: $24.60 | $250.00 |
DisclosureSEC source: 0001641172-25-003820 · ownership.xml · derivative · entry 1 Hayes William B · CIK 0001320940 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 500 shares Expires 2027-07-15 F1 · price: The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 20:15 UTC |
Meckler Jeffrey ADirector · Chief Executive Officer
|
Disposition to issuerStock Option (right to buy) · Derivative | 1,250 | $0.04 Strike: $355.20 | $46.25 |
DisclosureSEC source: 0001641172-25-003824 · ownership.xml · derivative · entry 6 Meckler Jeffrey A · CIK 0001506916 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,250 shares Expires 2025-06-28 F1 · price: The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 20:15 UTC |
Meckler Jeffrey ADirector · Chief Executive Officer
|
Disposition to issuerStock Option (right to buy) · Derivative | 1,563 | $0.04 Strike: $611.20 | $57.83 |
DisclosureSEC source: 0001641172-25-003824 · ownership.xml · derivative · entry 5 Meckler Jeffrey A · CIK 0001506916 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,563 shares Expires 2026-04-04 F1 · price: The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 20:15 UTC |
Meckler Jeffrey ADirector · Chief Executive Officer
|
Disposition to issuersStock Option (right to buy) · Derivative | 1,500 | $0.04 Strike: $425.60 | $55.50 |
DisclosureSEC source: 0001641172-25-003824 · ownership.xml · derivative · entry 4 Meckler Jeffrey A · CIK 0001506916 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500 shares Expires 2027-04-10 F1 · price: The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 20:15 UTC |
Meckler Jeffrey ADirector · Chief Executive Officer
|
Disposition to issuerStock Option (right to buy) · Derivative | 813 | $0.04 Strike: $425.60 | $30.08 |
DisclosureSEC source: 0001641172-25-003824 · ownership.xml · derivative · entry 3 Meckler Jeffrey A · CIK 0001506916 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 813 shares Expires 2027-05-01 F1 · price: The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 20:15 UTC |
Meckler Jeffrey ADirector · Chief Executive Officer
|
Disposition to issuerStock Option (right to buy) · Derivative | 3,750 | $0.04 Strike: $24.60 | $138.75 |
DisclosureSEC source: 0001641172-25-003824 · ownership.xml · derivative · entry 2 Meckler Jeffrey A · CIK 0001506916 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,750 shares Expires 2027-07-15 F1 · price: The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 20:15 UTC |
Meckler Jeffrey ADirector · Chief Executive Officer
|
Disposition to issuerStock Option (right to buy) · Derivative | 4,750 | $0.04 Strike: $536.00 | $175.75 |
DisclosureSEC source: 0001641172-25-003824 · ownership.xml · derivative · entry 1 Meckler Jeffrey A · CIK 0001506916 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,750 shares Expires 2027-12-11 F1 · price: The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 16:15 UTC |
MADDALUNA ANTHONY JDirector
|
Disposition to issuerStock Option (right to buy) · Derivative | 250 | $0.50 Strike: $355.20 | $125.00 |
DisclosureSEC source: 0001641172-25-003823 · ownership.xml · derivative · entry 3 MADDALUNA ANTHONY J · CIK 0001566333 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 250 shares Expires 2025-06-28 F1 · price: The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 16:15 UTC |
MADDALUNA ANTHONY JDirector
|
Disposition to issuerStock Option (right to buy) · Derivative | 250 | $0.50 Strike: $388.64 | $125.00 |
DisclosureSEC source: 0001641172-25-003823 · ownership.xml · derivative · entry 2 MADDALUNA ANTHONY J · CIK 0001566333 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 250 shares Expires 2026-06-28 F1 · price: The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 16:15 UTC |
MADDALUNA ANTHONY JDirector
|
Disposition to issuerStock Option (right to buy) · Derivative | 500 | $0.50 Strike: $24.60 | $250.00 |
DisclosureSEC source: 0001641172-25-003823 · ownership.xml · derivative · entry 1 MADDALUNA ANTHONY J · CIK 0001566333 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 500 shares Expires 2027-07-15 F1 · price: The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 20:15 UTC |
Pomerantz RogerDirector
|
Disposition to issuerStock Option (right to buy) · Derivative | 250 | $0.50 Strike: $355.20 | $125.00 |
DisclosureSEC source: 0001641172-25-003825 · ownership.xml · derivative · entry 3 Pomerantz Roger · CIK 0001614936 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 250 shares Expires 2025-06-28 F1 · price: The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 20:15 UTC |
Pomerantz RogerDirector
|
Disposition to issuerStock Option (right to buy) · Derivative | 250 | $0.50 Strike: $388.64 | $125.00 |
DisclosureSEC source: 0001641172-25-003825 · ownership.xml · derivative · entry 2 Pomerantz Roger · CIK 0001614936 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 250 shares Expires 2026-06-28 F1 · price: The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 20:15 UTC |
Pomerantz RogerDirector
|
Disposition to issuerStock Option (right to buy) · Derivative | 500 | $0.50 Strike: $24.60 | $250.00 |
DisclosureSEC source: 0001641172-25-003825 · ownership.xml · derivative · entry 1 Pomerantz Roger · CIK 0001614936 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 500 shares Expires 2027-07-15 F1 · price: The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 16:15 UTC |
Linscott Walt AddisonChief Operating Officer
|
Disposition to issuerStock Option (right to buy) · Derivative | 1,125 | $0.06 Strike: $610.24 | $66.38 |
DisclosureSEC source: 0001641172-25-003822 · ownership.xml · derivative · entry 6 Linscott Walt Addison · CIK 0001648585 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,125 shares Expires 2026-01-22 F1 · price: The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 16:15 UTC |
Linscott Walt AddisonChief Operating Officer
|
Disposition to issuerStock Option (right to buy) · Derivative | 2,500 | $0.06 Strike: $72.00 | $147.50 |
DisclosureSEC source: 0001641172-25-003822 · ownership.xml · derivative · entry 5 Linscott Walt Addison · CIK 0001648585 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires 2026-09-13 F1 · price: The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 16:15 UTC |
Linscott Walt AddisonChief Operating Officer
|
Disposition to issuerStock Option (right to buy) · Derivative | 1,125 | $0.06 Strike: $34.32 | $66.38 |
DisclosureSEC source: 0001641172-25-003822 · ownership.xml · derivative · entry 4 Linscott Walt Addison · CIK 0001648585 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,125 shares Expires 2027-02-17 F1 · price: The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 16:15 UTC |
Linscott Walt AddisonChief Operating Officer
|
Disposition to issuerStock Option (right to buy) · Derivative | 1,250 | $0.06 Strike: $25.72 | $73.75 |
DisclosureSEC source: 0001641172-25-003822 · ownership.xml · derivative · entry 3 Linscott Walt Addison · CIK 0001648585 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,250 shares Expires 2027-09-16 F1 · price: The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 16:15 UTC |
Linscott Walt AddisonChief Operating Officer
|
Disposition to issuerStock Option (right to buy) · Derivative | 750 | $0.06 Strike: $684.80 | $44.25 |
DisclosureSEC source: 0001641172-25-003822 · ownership.xml · derivative · entry 2 Linscott Walt Addison · CIK 0001648585 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 750 shares Expires 2027-10-23 F1 · price: The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 16:15 UTC |
Linscott Walt AddisonChief Operating Officer
|
Disposition to issuerStock Option (right to buy) · Derivative | 1,750 | $0.06 Strike: $684.80 | $103.25 |
DisclosureSEC source: 0001641172-25-003822 · ownership.xml · derivative · entry 1 Linscott Walt Addison · CIK 0001648585 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,750 shares Expires 2027-12-11 F1 · price: The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 16:15 UTC |
Sassi NirChief Financial Officer
|
Disposition to issuerStock Option (right to buy) · Derivative | 1,125 | $0.07 Strike: $610.24 | $79.88 |
DisclosureSEC source: 0001641172-25-003826 · ownership.xml · derivative · entry 7 Sassi Nir · CIK 0001760673 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,125 shares Expires 2026-01-22 F1 · price: The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.